Thursday 19 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterprise solutionsVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
CP+ Analysis

Merck KGaA's $0.75-a-share Rapid Micro bid caps a day of small-cap pharma consolidation

A cash tender for the maker of the Growth Direct microbial QC system sits alongside Richter–Mayne and Rosemont–Aytu, as smaller companies weigh sales, mergers and non-dilutive funding.

17 Nov 2026 · CompePharma editorial

What happened

Merck KGaA has signed a definitive agreement to acquire Rapid Micro Biosystems (RPID) through a cash tender offer at $0.75 per share, with closing expected in December 2026. RPID makes Growth Direct, an automated microbial quality control system. The timetable is short, as tender structures usually are, and it implies the parties expect a quick path to completion.

The material we have does not give the aggregate transaction value, the premium to RPID's prior share price, the minimum-tender condition, the financing, or any RPID financial results. We therefore don't characterise the price as cheap or full. What can be said is that the per-share figure is below $1 and that the consideration is all cash.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Sources

Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.

More CP+ AnalysisAll →